WeightWatchers rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'
WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The weight-loss company, previously championed by the likes of Oprah Winfrey, saw its stock spike this week after announcing that it will make copycats of Novo Nordisk's (NVO) Ozempic and Wegovy weight-loss drugs.
WeightWatchers to offer compounded GLP-1 weight-loss drugs
WeightWatchers said it will sell compounded versions of semaglutide — the key ingredient in Novo Nordisk's Ozempic and Wegovy.
WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy
Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.
WeightWatchers cashes in on popularity of weight loss drugs with compounded semaglutide
WW International (NASDAQ:WW), more commonly known as WeightWatchers, will now offer compounded semaglutide to its WeightWatchers Clinic members, expanding the accessibility of popular weight loss medications to its members at a more affordable price.
WeightWatchers stock pops on compounded GLP-1 weight-loss medication
Shares of WeightWatchers (WW) are climbing after the company announced a compounded GLP-1 medication starting at $129 as it seeks to make the weight-management solution "accessible and affordable." Catalysts Hosts Seana Smith and Madison Mills report more on the story and how it can compete with GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Ozempic and Eli Lilly's (LLY) Mounjaro.
WeightWatchers Adds Compounded GLP-1, Expanding Accessibility and Affordability of Weight Loss Medications
WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions that are underpinned by the comprehensive,
WeightWatchers CEO Sima Sistani out in abrupt exit, embraced weight loss drugs
WeightWatchers announced Friday that CEO Sima Sistani is no longer at the company, and independent board member Tara Comonte has stepped in to serve as interim CEO.
WeightWatchers is getting in on the off-brand weight loss drug game — and selling them cheap
WeightWatchers (WW) announced Tuesday that it is now offering off-brand weight loss drugs for one of the cheapest prices in the industry.
Low insurance coverage hampers access to weight-loss medications
In addition to availability, the cost of weight loss drugs like Wegovy and Zepbound is a major barrier preventing many Americans from using these medications.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing standards. WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs,
4029tv45m
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
WEIGHT WATCHERS SAYS IT WILL NOW OFFER ELIGIBLE MEMBERS COMPOUNDED ... It's part of a class of drugs known as GLP-1 ...
WeightWatchers offering compounded version of Ozempic, despite concerns expressed by FDA
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA ...
What's Going With WeightWatchers Stock On Wednesday?
WeightWatchers stock rises after the company announces compounded semaglutide offerings, addressing GLP-1 shortages while ...
WeightWatchers Is Offering Knockoff Wegovy. The Market Is Already Crowded.
The compounding pharmacies that supply knockoff Wegovy can only legally make it as long as it remains on the Food and Drug ...